Hill, Joshua A. http://orcid.org/0000-0002-7665-7100
Lee, Yeon Joo
Vande Vusse, Lisa K.
Xie, Hu
Chung, E. Lisa http://orcid.org/0000-0001-6224-6549
Waghmare, Alpana http://orcid.org/0000-0003-2268-9470
Cheng, Guang-Shing
Zhu, Haiying
Huang, Meei-Li
Hill, Geoffrey R.
Jerome, Keith R. http://orcid.org/0000-0002-8212-3789
Leisenring, Wendy M.
Zerr, Danielle M.
Gharib, Sina A.
Dadwal, Sanjeet
Boeckh, Michael
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (5K23AI119133)
Article History
Received: 21 September 2023
Accepted: 5 January 2024
First Online: 16 January 2024
Competing interests
: The authors declare the following financial competing interests. J.A.H.: Consulting for Allovir, Gilead, Karius, Symbio; research support from Allovir, Gilead, Karius, Merck. Y.J.L.: Research support from Karius, AiCuris, Scynexis, and Merck & Co Inc. A.W.: Consulting for Kyorin Pharmaceutical and Vir; research support from Allovir, Ansun Biopharma, Pfizer, Vir/GSK. G.R.H.: Consulting for Generon Corporation, NapaJen Pharma, iTeos Therapeutics, Neoleukin Therapeutics, Commonwealth Serum Laboratories, Cynata Therapeutics; research support from Compass Therapeutics, Syndax Pharmaceuticals, Applied Molecular Transport, Serplus Technology, Heat Biologics, Laevoroc Oncology, iTEOS therapetics and Genentech. D.M.Z.: Consulting for Allovir. S.S.D.: Consulting for Allovir, Asepticope, Merck, Takeda, Astellas Pharma; research support from Allovir, Ansun Biopharma, Karius, Merck. M.B.: Consulting for Allovir, Symbio, Evrys Bio; research support from Merck. L.K.V., H.X., E.L.C., G.S.C., H.Z., M.L.H., K.R.J., W.L., S.G. and S.J. declare no financial competing interests. All authors have no non-financial interests to declare.